PDGFRB and ovarian carcinoma: There are considerable efforts being made to validate PDGFR as a novel cancer target, and several inhibitors of PDGFR and related kinases are being developed or have already entered clinical trials for women with ovarian cancer, such as imatinib, sorafinib and sunitinib [38–41,  48].